Objective: Describe the incidence of cancer in a large cohort of patients with myotonic dystrophy type 1 (DM1) and to unravel the underlying molecular mechanisms.
Myotonic muscular dystrophies are a group of autosomal dominant, multisystem diseases encompassed by 2 subtypes. Myotonic dystrophy type 1 (DM1), also known as Curschmann-Steinert disease (OMIM: #160900), is caused by the expansion of an unstable trinucleotide (CTG) repeat expansion in the 39 untranslated region of a DMPK kinase gene located in chromosome 19 . The type 2 (DM2) (OMIM #602668) is originated by a tetranucleotide (CCTG) repeat expansion in intron 1 of the CNBP gene. DM1 displays a more severe phenotype than DM2 and represents the most common adult muscular dystrophy, with an estimated prevalence ranging from 0.5 to 18 of 100,000 people, 1 although the disease prevalence is higher in some regions such the province of Gipuzkoa in the Spanish Basque Country.
usually associated with cataracts developed in presenile age, to severe neonatal forms with more than CTG 1,000 repeats, associated with severe developmental delays. Life expectancy is reduced because of complications derived from muscle weakness, respiratory and cardiac involvement, neoplasms, and metabolic disturbances such as hypercholesterolemia or diabetes. 3, 4 In 1965, Cantwell and Reed 5 first reported an association between DM1 and pilomatricoma, a rare and benign cutaneous tumor. Since then, several case reports describing benign and malignant neoplasms in virtually any location have been published. 6 Furthermore, in recent years, large epidemiologic studies performed in population-or clinical-based cohorts provided evidence of increased risk of malignant tumors in patients with DM. [7] [8] [9] [10] Excess risks of endometrium, ovarian, thyroid, skin, eye, and colon cancer were observed in 2 of the 3 studies, while brain cancer excess risk was observed in one study. A follow-up study including 911 patients with DM showed that females with DM1 were more likely to develop cancers. 11 Several studies have shown no association between the size of leukocyte repeat expansion and cancer risk in those patients 6 and the underlying causes, and the biological mechanisms of the susceptibility for developing tumors are still unknown.
In this study, we quantified cancer risk in the clinically and genetically well-characterized Gipuzkoa Myotonic Dystrophy Cohort, and used gene expression analysis to identify possible molecular mechanism of cancer susceptibility in those patients. The cohort includes all patients diagnosed with DM in the past 30 years in an area with one of the largest DM1 prevalences worldwide.
METHODS Study population. Data from patients were retrospectively obtained from the medical records of the Gipuzkoa historical myotonic dystrophy cohort, established in 1985. We identified 503 patients with a molecularly confirmed DM diagnosis between 1985 and 2013. We excluded 4 patients with DM2 diagnosis and 75 patients with DM1 because of lack of data or they were lost to follow-up.
From patients' medical records, we extracted the following information: sex, age at the time of study enrollment and age at death, nucleotide expansion size (CTG triplets), calendar year of diagnosis, disease severity assessed using the Muscular Impairment Rating Scale (MIRS) 12 at the time of the last visit, age and calendar year of cancer diagnosis, and cancer anatomical site. Diagnoses of all types of malignant neoplasia were coded using ICD, Ninth Revision. Death causes were coded using ICD-10 (2014 version).
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Genetic analysis. The CTG repeat was measured at the time of DM1 diagnosis by conventional PCR and Southern blot. Conventional PCR was performed with 100 ng of genomic DNA using gene-specific primers flanking the DMPK CTG repeat. All normal homozygotes and expanded alleles were confirmed with Southern blot. We included patients with 40 or more CTG repeats because of the demonstrated instability of the fragment size from this threshold, independently of the presence or absence of clinical manifestations, assuming that if we eliminate the cases considered as premutations, we neglect a possible effect of genomic condition over cancer prone.
Statistical analysis. Follow-up started at the date of DM1 diagnosis and ended at the date of first cancer diagnosis, death, or last visit. We calculated standardized incidence ratios (SIRs) by dividing the observed numbers of cancer by the expected numbers for all cancers combined and cancer-specific anatomical sites, overall and stratified by sex. Expected numbers were calculated by multiplying the age-and sex-specific incidence rate from the Basque population cancer registry 14 by the person-years of the study cohort. SIRs were obtained for all types of cancers except for basal cell carcinoma of the skin because this type of cancer is not collected in the registry. Confidence intervals (CIs) were calculated using the Poisson distribution.
Mean repeat length was compared for patients with and without cancer using the Student t test. All tests were considered statistically significant if p , 0.05. Statistical analysis was performed using Stata/SE 12 (StataCorp LP, College Station, TX).
Transcriptomic analysis. This analysis included 10 patients with DM1 (5 women, 5 men; mean age: 43.4 6 5.16 years; expansion size: 750 6 306 CTG triplets) who had moderate or severe clinical manifestations (MIRS median score 5 3, range 3-5) and no malignancy before or at the time of blood collection and 10 age-and sex-matched healthy controls. We extracted RNA from peripheral blood mononuclear cells using the LeukoLOCK Total RNA Isolation System (Life Technologies, Carlsbad, CA). For the RNA extraction, we use a 2-step protocol, first with the miRNesay Mini Kit (QIAGEN, Valencia, CA) followed by automated RNA extraction in the QIAcube. Large-scale gene expression was measured by the Human Gene 1.0 ST Affymetrix microarray (Affymetrix, Santa Clara, CA). RNA integrity was checked with an Agilent RNA 6000 Nano Kit (Agilent Technologies, Inc., Santa Clara, CA). Samples with an RNA integrity value above 7 were accepted to be processed. Three hundred nanograms of total RNA were used for microarray analysis following the manufacturer's instructions.
We analyzed gene expression differences in patients with DM1 and healthy controls, and in a second step, we studied the differences between patients with DM1 by sex. Results of the microarray data were extended by reverse transcription-PCR in an additional DM1 male (n 5 16) and female (n 5 25) subset of patients.
Western blot analysis. We did a Western blot of the protein products of the targets altered in the transcriptomic analysis. Immunoblots were performed as previously reported. 15 We used ab16123 (Abcam, Cambridge, UK) for p16
Ink4a detection and A-5441 (Sigma, St. Louis, MO) for b-actin and horseradish peroxidaselinked anti-rabbit or anti-mouse (Santa Cruz Biotechnology, Dallas, TX) secondary antibody at a 1:2,000 dilution. Detection was accomplished by chemiluminescence using Novex ECL Chemi Substrate (ThermoFisher Scientific, Waltham, MA).
Standard protocol approvals, registrations, and patient consents. This study was approved by the Donostia Universitary Hospital Ethical Board and conducted in accordance with the Declaration of Helsinki ethical standards.
RESULTS
Cancer incidence rate in patients with DM1.
The study included 424 patients with DM1; 214 (50.5%) of them were women. Mean CTG repeat expansion size at the time of DM1 diagnosis was 684 6 535 CTG triplet expansion (range: 43-2,000 CTG repeats). One hundred thirty-seven patients were deceased at the time of analysis. Additional demographic and clinical features of the patients are shown in table 1. The most common causes of death were diseases of the respiratory system (38%), the circulatory system (24.1%), and neoplasms (15.3%); causes of death were unknown in 15.3% of the patients ( Transcriptomic analysis of patients with DM1. As previously described, 16 we observed differences in gene expression between healthy men and women (figure 1, A and B). Similar sex differences were detected in the transcriptome of patients with DM1 ( figure 1, A-C) . Compared to healthy controls, patients with DM1 had an upregulation of RNA5SP211, an unknown pseudogene, and downregulation of TAS2R13, a subtype of taste receptors.
When we analyzed the results according to sex, we found that EMR4P (a hormone receptor), CD24 (a glycoprotein expressed on mature granulocytes and B cells), PLA2G7 (a platelet activating factor), and caspase-5 (a gene implicated in apoptosis) were significantly upregulated in men ( figure 1, B and C) . Moreover, we identified 11 genes differentially expressed in women with DM1, including upregulation of a subtype of histone (HIST1H2AK) and pyruvate dehydrogenase kinase 4 (PDK4), and downregulation of 3 microRNA precursors (pre-miR-3978, pre-miR-141, and premiR-200c), a transcription factor (ZEB2), an olfactory receptor (OR52K2), an inhibitory receptor of myeloid cells (CLEC12B), myoferlin (a protein that has a role in calcium-mediated membrane fusion events, membrane regeneration and repair, and subsequently in muscle weakness), a death-associated protein kinase (DAPK1), and MS4A4E ( figure 1, B and C) . The same results were observed in an independent validation set of patients ( figure 1, D and E) . Specifically, the differentially expressed levels of 13 of 17 genes detected in the array were confirmed in the validation cohort.
Identification of miR-200c/miR-141 cluster associated with the cancer susceptibility phenotype in DM1. The miR-200c/miR-144 and miR-3978 precursors were downregulated in the group of women with DM1 in the array and validated in the extended cohort ( figure 2, A and B) . Of note, the mature forms miR-200c-5p, miR-141-3p, miR-141-5p, and miR-3978 were downregulated in the cohort of women with DM1 ( figure 2C ). On the contrary, the expression was slightly elevated in men, revealing a sex differential expression of those miRs in DM1 ( figure 2, C and D) . Because the BMI1 and ZEB family member oncogenes are reported as miR-200 target genes, [17] [18] [19] [20] [21] [22] we measured their expression finding that ZEB1 and ZEB2 were decreased while BMI1 levels were upregulated in the group of women with DM1 ( figure 2E) . Moreover, the expression of p16 Ink4a tumor suppressor, a known target of BMI1 epigenetic silencing, was lower at both messenger RNA and protein level in the same group of women with DM1 ( figure 2, F and G) . DISCUSSION There is recent accumulating evidence that patients with DM1 are at high risk of developing cancers. Confirming these findings in an independent study and in different DM populations is important for patient clinical management. Using data from a large molecularly confirmed cohort of patients with DM1, we showed a statistically significant excess risk of endometrium, ovary, thyroid, and brain cancer. In the largest epidemiologic cohort published so far accounting for more than 1,600 patients with DM1 and DM2, Gadalla et al. 7 found an apparent high risk of cancers of the endometrium, brain, ovary, and colon, and possibly thyroid and choroidal melanoma and nonmelanoma skin cancers. In smaller studies, Win et al. 8 reported a higher risk of developing thyroid cancer and choroidal melanoma whereas Mohamed et al. 9 concluded that there was a high risk of thymoma, gynecologic, and lung cancer. Recently, in a small published cohort, Bianchi et al. 10 found that skin, thyroid, ovary, and breast cancers were most frequent in patients with DM.
Our results are coincidental with those reported by Gadalla et al. in a population-based study of more than 1,600 patients with DM 7 with the exception of colorectal cancer. However, the CI (0.94-3.92) of this type of cancer was near to significance values and the smaller sample size in our cohort could explain this result. Of note, colorectal cancer was also the most frequent among those patients who had 2 or more cancers. The excess risks of thyroid, 8, 10 endometrium, and ovary 9, 10 were also found in smaller studies. Of importance, and as also indicated by Gadalla et al., 4, 7 we did not find an overrepresentation of screening-related cancers (i.e., breast and prostate), strongly suggesting that the results are genuine and not biased by the close medical surveillance in patients with DM. The fact that there are no incidence and mortality cancer differences between the Basque and other regions in Spain 23 led us to eliminate the notion that the excess cancer in this population could be explained by other genetic factors rather than the DM1 condition itself.
Our data show that malignancies developed at a mean age of 46.6 6 14.7 years. In agreement with previous reports, 3, 24 cancers represented the third leading cause of death after respiratory and circulatory diseases in our DM1 population. A progressive increase in cumulative incidence of cancer mortality has been previously reported (2% by age 50 to 6% by age 70). 4 Another striking feature is the apparent absence of a correlation between cancer risk and nucleotide repeat length. This result could be potentially biased for methodologic reasons because the CTG repeat expansion size was measured years before cancer emergence and also because of the somatic instability that characterizes DM1. Based on the differences found between tumoral and healthy tissues in patients with DM1, some authors have suggested that there might be an underlying independent mechanism of somatic instability in the tumoral tissue. [25] [26] [27] However, the later contrast with the recent finding that MBLN1, a splicing factor sequestered in the nuclear foci of DM1 cells, which correlates with CTG expansion size, could be implicated in the physiopathology of the progression of certain cancers. 28 Our results showing a differential transcriptional profiling of several genes previously linked to cancer, such as PDK4, 29 DAPK1, 30 CASP5, 31 and PLA2G7 32 in patients with DM1 compared to healthy controls, open the door to a mechanistic explanation of this increased oncogenic risk in DM1. In addition, we observed a downregulation of miR-200c, miR-141, and miR-3978 mature and precursor forms in female patients with DM1. Of note, 2 of them, miR-200c and miR-141, belong to the same miR-200 tumor suppressor cluster. Lower levels of the miR-200c family members were detected in tumor tissues and blood-derived samples in a wide range of cancer types. 33 This decline was associated with tumor progression and poor prognosis including metastasis. 34, 35 The miR-200 family has several well-described oncogenes as downstream targets, likely the ZEB family and the polycomb group gene BMI1 becoming crucial targets. [18] [19] [20] [21] 36 Our results show that these genes are altered in both sexes of patients with DM1 supporting the relevance of this molecular signaling on the disease. In particular, women with DM1 express elevated BMI1 levels, while ZEB1 and 2 are decreased. The existence of such alterations in patients with severe disease and no cancer prompted us to hypothesize that the downregulation of miR-200 cluster members have a role in cancer susceptibility, and the consequent upregulation of BM1 instead of through ZEB may be required for its development. In support of this idea, (1) ZEB factors are epithelial-mesenchymal transition inducers and their role has been associated with metastasis rather than tumor formation; (2) the expression of p16
Ink4a tumor suppressor, a critical target of BMI1, inversely correlates with BMI1 levels in patients with DM1; and (3) miR-200 and BMI1 play an important role in the maintenance of adult stem cells and tumor-initiating cells in many organs. Of note, many of the cancers detected in patients with DM1 emerge in tissues with a high rate of cellular replications.
Taken together, our findings support a model through a coordinated action between the miR-200 expression and its downstream targets ZEB1/2 and BMI1. In support of this notion, there is a close functional link between the miR-200 family and ZEB factors and BMI1 in a double-negative feedback loop, respectively. Thus, the activation of one of them affects the expression and activity of the others. 37, 38 Our study strength includes the population-based design (all patients with DM1 in the Gipuzkoa population were included), and therefore no selection bias exists. We are limited by the lack of information of known cancer risk factors such as smoking, diet, lifestyle, environmental influences, and alcohol intake among others. Patients with DM1 have more obesity and the prevalence of tobacco smoking is higher than in the general population, 39 so these risk factors might have had a confounding role in our results and should be considered when planning longitudinal studies. However, a recent study suggested that lifestyle factors in patients with DM1 do not explain the observed excess risk of cancers. 10 We believe that our study provides independent cancer site-specific confirmation of recently reported excess cancer risks as part of the DM1 phenotype, especially for women, and suggests that this association could be more related to a transcriptomic regulation of oncogenic pathways than a direct consequence of the DM genomic signature.
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